Consilium medicum начало :: поиск :: подписка :: издатели :: карта сайта

БИБЛИОТЕКА CONSILIUM-MEDICUM  
Том 04/N 1/2004 Метаболический синдром

Список литературы


И. Е. Чазова*, В. Б. Мычка**

*Доктор медицинских наук, профессор, руководитель отдела системных гипертензий Института кардиологии им. А.Л.Мясникова РКНПК МЗ РФ. , **Кандидат медицинских наук, научный сотрудник отдела системных гипертензий Института кардиологии им. А.Л.Мясникова РКНПК МЗ РФ.

1. 1999 World Health Organization – International Society of Hypertension. Guidelines for the Management of Hypertension. J Hypertension 1999; 17 (2): 151–183; 30(Suppl. 2): 1–7.
2. Abernethy DR. The pharmacokinetic profile of amlodipine. Am J Cardiol 1989; 64: 101–201.
3. Accili D, Cama A, Barbetti F et al. Insulin resistance due to mutation of the insulin receptor gene: an overview. J Endocrinol Invest 1992; 15: 857–64.
4. Ackroff K, Sclafani A. Effects of the lipase inhibitor orlistat on intake and preference for dietary fat in rats. Am J Physiol 1996; 271(1Pt2): R48–54.
5. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15 (7): 539–53.
6. Alberti KJ, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15: 539–53.
7. Alessi MC, Perietti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997 May; 46(5): 860–7.
8. Ambrosioni E, Lafar M, Degaufe JP et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomized double-blind controlled studies. J.Hypertens.1998; 16: 1677–84.
9. American Diabetes Association. Management of Dyslipidemia in Adults With Diabetes. Position Statement. Diabetes Care 1999; 22: 56–9.
10. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183–97.
11. Ames RP, Hill PH. Antihypertensive therapy and risk of coronary heart disease. J Cardiovasc Pharmacol 1982; 4 (Suppl. 2): S206–16.
12. Ames RP. Negative effects of diuretic drugs on metabolic risk factors of coronary heart disease: possible alternative drug therapies. Amer J Cardiol 1983; 51: 632–8.
13. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med. 1997; 14 (Suppl. 5): S1–S85.
14. Anderson A, Morgan O, Morgan T. Duration of antihypertensive effect of perindopril enalapril and captopril. Hypertens 1993; 21: 568.
15. Anderson A, Morgan O, Morgan T et al. Effectiveness of blood pressure control with once daily administration of enalapril and perindopril Am J Hypertens 1994; 7: 371–3.
16. Anderson EA, Hoffman RP, Balon TW et al. Hyperinsulinemia produced both sympathetic neuronal activation and vasodilatation in normal humans. J Clin Invest 1991; 87: 2246–52.
17. Appel S, Rufenacht T et al. Lack of Interaction Between Fluvastatin and Oral Hypoglycemia Agents in Healthy Subjects and in Patients with Non–Insulin-Dependent Diabetes Mellitus. Am J Cardiol 1995; 76: 29A–32A.
18. Armstrong B, Stevens N, Doll R. Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English woman. Lancet 1974; 2: 672–5.
19. Arner P. Catecholamine-induced lypolysis in obesity. Int J Obes Relat Metab Disord 1999; 23 (Suppl. 1): 10–3.
20. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodinamyc hypertension. Am J Cardiol 1991; 68: 61–47.
21. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713–24.
22. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B–12B.
23. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Association of hyperlipidemia, diabetes mellitus and mild obesity. Acta Diabetol Lat 1967; 4: 572–90.
24. Baillie GM, Sherer JT, Weart CW. Insulin and coronary artery disease: is syndrome X the unifying hypothesis? Ann Pharmacother. 1998; 32: 233–47.
25. Bak JF, Schmitz O, Niels SS, Pedersen O. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes. 1989; 38: 1343–50.
26. Bauer JH, Brooks CS, Weidmann I et al. Effects of diuretic and propranplol on plasma lipoprotein lipids. Clin Pharmacol Ther 1981; 30: 35–43.
27. Belichenko O, Sharia M, Shapkina L, Sitina V, Michko V, Kiseleva O. Clinical application of magnetic resonance imaging in the evaluation of treatment efficacy in patient with adrenal pathology and arterial hypertension. Tenth European meeting on hypertension, Geteborg (Sweden) May 29 – June 3, 2000.
28. Bell PM, Hadden DR. Metformin. J Clin Endocrinol Metab 1997; 26(3): 523–37.
29. Bengtsson BA. The consequences of growth hormone deficiency in adults. Acta Endocrinol 1993; (Suppl. 2): 128.
30. Bergman N. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Computer methods and programs in biomedicine 1986; 23 (2): 113–22.
31. Bergman R, Phillips L, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man. J Clin Invest 1981; 68: 1456–67.
32. Bergman RN, Prager R, Volund A et al. Equivalence of the insulin sensitivity index in man derived by the minimal model method the englycemic glucose clamp. J Clin Invest 1987; 79: 790–800.
33. Bertherat J. Nouroendocrine regulation of growth hormone. Endocrin 1995, 132: 12–24.
34. Berthezene F. Non-insulin-dependent diabetes and reverse cholesterol transport. Atherosclerosis 1993; 102: 63–7.
35. Best J, Nicholson GO, Neal et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diabetes Nutr Metab 1996; 9: 74–80.
36. Bianchi S, Bigazzi R et al. Hyperinsulinemia in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23: 681–8.
37. Bianchi S, Bigazzi R, Quinones Galvan A et al. Insulin resistance in microalbuminuric hypertension: sites and mechanisms. Hypertension 1995; 26: 789–96.
38. Bjorntop P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Aterosclerosis 1990; 10: 493–496.
39. Bjorntorp P. Neuroendocrine abnormaliles in human obesity. Metabolism. 1995; 132: 12–24.
40. Bjorntorp P. Neuroendocrine abnormalities in human obesity. Metabolism 1995; 132: 12–24.
41. Bjorntorp P. Obesity. Lancet 1997; 350: 423–6.
42. Black D, Bakker-Arkema R, Nawrocki J An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158: 577–84.
43. Black HR, Curb JD, Pressel S et al. Systolic hypertension in the Elderly Program (SHEP). Hypertension 1991; 17 (Suppl. 11): 11–1–171.
44. Blankestijn PJ et al. Nebivolol. An acute and long term study in essential hypertension. Drug Invest. 1991; 3 (Suppl. 1): 152–4.
45. Bogieva R, Mychka V, Chazova I. Influence of Glucobay treatment on blood pressure, glucose and lipids metabolism, weight and body mass index in patients with mild arterial hypertension and metabolic syndrome. 13th European meeting on Hypertension, Milan, Italy, June 13–17,2003.
46. Boor R. Familiar insulin resistance diabetes associated with acantosis nigricans, policystic ovarian hypoganadism, pigmentary retinopathy, labyrintine deafness and mental retardation. J Am Med Genet 1993; 45(5).
47. Borkan GA, Sparrow D, Wisnrewski C, Vokonas P.S. Body weight and coronary disease risk: patterns of risk factor change associated with lon-term weight change. The normative ageing study. Am J Epidemiol. 1986; 124: 410–9.
48. Bossaller C, Auch-Schwelk W, Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelial-dependent vascular relaxion. Agets Actions 1992; 38: 171–7.
49. Bowman AJ et al. Nitric oxide mediated venodilator effects of Nebivilol. Br J Clin Pharm. 1994; 38: 199–204.
50. Brands MW, Mizelle HL, Gaillard CA et al. The hemodynamic response to chronic hyperinsulinemia in conscious dog. Am J Hypertens 1991; 4: 164–8.
51. Brands MW, Mizzelle HL, Gaillard CA et al. The hemodynamic response to chronic hyperinsulinemia in conscious dog. Am J Hypertens 1991; 4: 164–8.
52. Bray GA. Pathophysiology of obesity. Am J Clin Nutr 1992; 55: 4889–993.
53. Breslin E, Posvar E, Neub M et al. A pharmacodynamic and pharmacokynetic comparison of intravenous quinaprilat and oral quinapril. J Clin Pharmacol 1996 May ; 36(5): 414–21.
54. Broun A. Treating patients with documented atherosclerosis to national cholesterol education program–recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. JACC 1998; 32: 665–72.
55. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 2000; 356: 366–72.
56. Brown MJ, Palmer CR, Costaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in Hypertension Treatment (INSIGHT). Lancet 2000; 356; 29: 366–72.
57. Bruttomesso D, Pianta A, Verio A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99–105.
58. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol–lowering interventions. Artherioscler Thromb Vasc Biol 1999; 19: 187–95.
59. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s” disease of the omentum? Lancet 1997; 349 (9060): 1210–3.
60. Burges RA. Dodd MG, Gardiner DG. Pharmacologic profile of amlodipine Am J Cardiol 1989; 64: 101–201.
61. Camus J Goutte, diabete, hyperlipemie: un trisyndrome metabolique. Rev Rhumat 1966; 33: 10–4.
62. Chalmers J et al. WHO–ISH Hypertension Guidelines Committee. 1999 World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertension 1999; 17: 151–85.
63. Chang PC, van Veen S, Vermeij P, van Brummelen P. Double–blind compason of the b1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S58–60.
64. Chazova I, Mychka V, Sheinina N. The influence of perindopril on carbohydrate and lipid metabolism in arterial hypertensives with metabolic syndrome. 19-th Scientific Meeting of the International Society of Hypertension; 12th European Meeting on Hypertension; June 23–27, 2002. Prague.
65. Chazova I, Mychka V, Gornostaev V. The efficiency and safety of use of combined drug Logimax in patients with mild-to-moderate hypertension and type 2 diabetes mellitus. 13-th European meeting on Hypertension, Milan, Italy, June 13–17, 2003.
66. Chiasson J et al. The STOP–NIDDM trial. An international study on efficacy of an a-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care 1998, 21, 1720–5.
67. Chiu KC, McCarthy JE. The insertion allele at the angiotensin1–converting enzyme gene locus is associated with insulin resistance. Metabolism 1997; 46: 395–9.
68. Clausen JO, Hausen T, Bjorbaek C et al. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 1995; 346: 397–402.
69. Cleophas Ton J Experimental evidence of selective antagonistic action of Nebivolol on b1-adrenergic receptors. J Clin Med 1998; II: 1–8.
70. Cockroft JR, Chowenczyk PHJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence of L-arginine/NO-dependent mechanism. Journal Pharmacology Experimental Therapeutics 1995; 274: 1067–71.
71. Cole SA, Aston CE, Hamma RF et al. Association of a Pvull RFLP at the lipoprotein lipase locus with fasting insulin levels in Hispanic men Genet Epidemiol 1993; 10: 177–88.
72. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Clin Orthop 1991; 262: 3–11.
73. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335: 827–38.
74. Collins R, Yusuf S. HPS–Simvastatin and anti-oxidants. Americal Heart Association Scientific Sessions; November 11–14, 2001; Anaheim, California, Plenary Session VII: Late–Breaking Clinical Trials.
75. Conde K, Vergara-Jinenez M. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 1996; 37: 2372–82.
76. Crome P, Keen H. Partial lipodystrophy and insulin-resistant diabetes. Diabet Metab 1978; 4(2).
77. Cupples LA. Risk factors for cardiovascular death. Am Heart J 1993; 125: 863–72.
78. Curb J, Borhani N, Blaszkowski TP. Long–term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253; 22: 32
79. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110.
80. Davis BR, Cutler JD, Gordon DJ et al. Rationale and design for the Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342–60.
81. Davis SN, Colburn C, Robbins R et al. Evidence that the brain of the conscious dog is insulin sensitive. J Clin Invest 1995; 95: 593–602.
82. De Cesaris R, Ranieri G, Adriani A et al. A comparative study of the effects of lisinopril and quinapril administered once a day in essential hypertension. (In italian). Minerva Med 1990. Jul 1990; 31; 81 (7–8): 541–16.
83. De Cree J et al. Double blind placebo-controlled cross-over study evaluating the acute haemodynamic effects of dl-Nebivolol 5 mg, d-Nebivolol 2,5 mg an l-Nebivolol 2,5 mg in healthy volunteers. JRF Clinical Research Report on R67555 NO–35. February 1989.
84. Decode Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia 1999; 42: 654–74.
85. DeFronzo R, Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dislipidemia and atherosclerotic cardio-vascular disease. Diabetes Care 1991; 4 (3): 173–94.
86. DeFronzo RA, Agus Z. The effect of glucose and insulin on renal electrolyte transport. J Clin Invest. 1976; 58: 83–90.
87. DeFronzo RA, Barzilai N, Simonson DC. Machanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73(6): 1294–301.
88. DeFronzo R.A, Dvis PJ. The effect of insulin in renal handing of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845–55.
89. Despres JP. The impact of orlistat on the multifactorial risk profile of abdominally obese patients. Diabetes 1998; 48: 1–307.
90. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334 (15): 952–57.
91. Despres JP, Moorjani S, Lupien PJ et al. Regional distribution of body fat, plasma insulin, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497–511.
92. Dominguez LJ, Barbagallo M, Jacober SJ et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997; 10 1349–55.
92a. Donnely R. Clinical implications of indapamide sustained release 1.5 mg in hypertension. Clin Pharmacokinetics 1999; 37 (Suppl. 1): 21–32.
93. Dorella M, Giusto M et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin–resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81: 1568–74.
94. Doria A, Fioretto P, Avogaro A et al. Insulin resistance is associated with high sodium–lithium counter–transport in essential hypertension. Am J Physiol 1991; 261: E684–691.
95. Dowse GK, Zimmet PZ, Gareebo H et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 1991; 14: 271–82.
96. Draznin B, Sussman KE et al. Possible roie of citosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 1988; 82: 1848–52.
97. Drent M, Larsson I, William-Olsson T et al. Orlistat (Ro 18–0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19 (4): 221–6.
98. Ducimetiere P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle–aged men and the risk of coronary heart disease: The Paris Prospective Study. Int J Obes 1986; 10: 229–40.
99. Dzau V, Julius S, Weber M et al. ASCEND (Accupril Study of clinical, Economic, and Dose Titration End Points): effect of up titration and compliance on response rate. Am J Hypertens 1996 Apr 9; (PT 2): 72.
100. Elevated fasting insulin predict hypertension: the ARIC study. Liese AD, Mayer-Davis EJ, Chembless LE, Folsom AR, Sharret AR, Brancati FL, Heiss G for the Atherosclerosis Risk in Communities Study Investigators. J Hypertansion 1999; 17: 11690–1177.
101. Elkeles RS, Diamond JR et al. The SENDCAP Study Group. Cardiovascular outcomes in type 2 diabetes. Diabetes Care 1998; 21: 641–8.
102. Ernsberger P, Ishizuka T, Liu S et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rats. J Pharmac Exp Therap 1999; 288: 139–47.
103. Estasio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with non insulin dependent diabetes and hypertension N Engl J Med 1998; 338: 645–52.
104. Evans DJ, Murray R, Kisselbah AH. Relationship between skeletal muscle insulin resistance, insulin mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. J Clin Invest 1984; 74(4): 1515–25.
105. Everhart JE, Petitt DJ, Benneth PH et al. Duration of obesity increases the incidence of NIDDM. Diabetes 1992; 41: 235–40.
106. Expert Panel on Detection, Evalution, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the Nanional Cholesterol Education Program (NCEP) Exrert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486–97.
107. Fernander–Real SM, Gutierres C, Ricart W et al. The TNF-a gene Neo I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 1997; 46: 1468–72.
108. Ferranini E, Buzzigoli G et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 370–7.
109. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med. 1987; 317: 350–7.
110. Ferrannini E, Haffner SM, Mitchell BD et al. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416–22.
111. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S. Insulin resistance, hyperinsulinemia and blood pressure. Role of age and obesity. Hypertension 1997; 30: 1144–9.
112. Ferrari P, Weidmann P. Altered insulin sensitivity, hyperinsulieamia and dyslipidaemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589–96.
113. Ferrari P, Weidmann P. Insulin, insulin sensitivity and hypertension. J Hypertens 1990; 8: 491–500.
114. Filer JS. Leptin resistance and obesity. Presented at the 60-th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
115. Floras JS, Harak K. Sympathoneural and hemodynamic characteristiks of young subject with mild essential hypertension. J Hypertens 1993; 11: 647–55.
116. Florkowski CM, Richardson MR, Le Guen C, Jennings PE, Jones AF, Lunec J Effect of gliclazide on thromboxane B2 parameters of hemostasis, lipid peroxides and fluorescent IgG in type 2 diabetes mellitus. Diabetologia 1988; 31:490A.
117. Fogari R et al. b-Blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (Suppl. 5): S76.
118. Fogari R, Zoppi A, Corradi L et al. b-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 534–9.
119. Fogari R, Preti P, Banderali A et al. ACE–inhibition but not angiotensin II antagonism improves fibrinolisis and sensitivity in hypertensive post-menopausal women. J Hypertens 1999; 17(Suppl. 3): S143.
120. Fontbonne A., Charles M.A., Juhan-Vague I et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO study group. Diabetes Care 1996 Sep; 19(9): 920–6.
121. Fontbonne A, Eschwege E et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 1-yeas follow uh of the Paris Prospective Study. Diabetologia 1989; 32: 300–4.
122. Fortaine KR, Cheskin LJ, Barofsky I. Health–related quality of life in obese persons seeking treatment. J Fam Pract 1996; 43: 265–270.
123. Fraze E. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1995; 61.
124. Frei M, Kuster L, Gardosch von Krosigk PP et al. Moxonidine and hydrochlortthiazide in combination: a synergistic antihypertensive effect. J Cardiovsc. Pharmaco 1994; 24: S25–8.
125. Freidman JE, Ishizuka, Liu S. Antihyperglycemic activity of moxonidine: metabolic and molecular effects of obese spontaneously hypertensive rats. Blood pressure 1998; 7 (Suppl. 3): 32–9.
126. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
127. Frithz G. Influense on plasma–insulin and blood–glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001, 4: 229–30.
128. Fuciyama K, Higashi G, Yoshida K et al. .A clinical phase I study of quinapril Japanese. Yakuri To Chiryo 1991; 19:167–98.
129. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875–81.
130. Gerstein HC, Bosch J, Pogue J. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes . The MICRO–HOPE study. Diabetes Care 1996; 19: 1225–8.
131. Giulgliano D, Quatraro A, Consoli G et al. Metformin for obese insulin–related diabetic patients: improvement in glicaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44 (2): 107–12.
132. Gluck Z, Weidmann P, Mordasini R. Increased serum low-density lipoprotein cholesterol in men, treated short-term with the diuretic chlorthalidone. Metabolism. 1980; 29: 240–5.
133. Gmerek A, Yang R, Bays H et al. Atorvastatin causes a dosedependent reduction in LDL-C and triglycerides (abstract). In 66th Congress of the European Atherosclerosis Society Abstract Book: 1996 Jul 13–17; Florence (Italy): 212.
134. Goldschmidt MG, Barret-Conner E, Edelstein SL et al. Dyslipidaemia and ischaemic heart disease mortality among men and women with diabetes. Circulation 1994; 89: 991–7.
135. Gornostaev V, Mychka V, Sergienko V, Chazova I. Feature of brain perfusion autoregulation reserve in patients with arterial hypertension and metabolic syndrome. 19th Scientific Meeting of the International Society of Hypertension; 12th European Meeting on Hypertension; June 23–27, 2002, Prague.
136. Gornostaev V, Mychka V, Chazova I, Dvoskina I, Sergienko V. Brain perfusion autoregulation reserve in patients with arterial hypertension and metabolic syndrome. European Journal of Nuclear Medicine and Molecular Imaging 2003; 30 (2): S254.
137. Gornostaev V, Mychka V, Dvoskina I, Sergienko V, Buvaltsev V, Chazova I. Efficacy of Nebivolol 24-weeks monotherapy on carbohydrates and lipids metabolism, blood pressure and brain perfusion in patients with metabolic syndrome. 13-th European meeting on Hypertension, Milan, Italy, June 13–17, 2003.
138. Gosse PH, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: LIVE study. J Hypertens 2000; 18: 1465–75.
139. Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents Clin Exp Hypertens 1999; 21: 167–79.
140. Gray RP, David L, Patterson H, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscl Thromb 1993; 13: 415–20.
141. Grimaldi A, Heurtier A. Epidemiology of cardiovascular complication of diabetes. Diabetes Metab 1999; 25 (Suppl. 3): 12–20.
142. Grimm RH, Grandits GA, Culter JA et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of Mild hypertension Study. Arch Intern Med 1997; 157: 638–48.
143. Grimm RH, Grandits GA, Culter JA, Stewart A.L. et all. Relationship of quality of life measures to long–term lifestyle and drug treatment in the treatment of mild hypertension study (TOMHS). Arch Intern Med 1997; 157: 638–48.
144. Guy-Grand B. The clinical uses of dexfenfluramine in the management of obe-sity. Rev Contemp Pharmacother 1991; 2(2): 115–28.
145. Haefeli WE, Linder L, Lusher TF. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans. Hypertension 1997 Oct; 30(4): 912–7.
146. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin – resistant hypertensives. J Hypertension 1999; 17(suppl. 3): S29–39.
147. Haffner PA, Valder RA, Hazuda HP et al. Prospective analysis of the insulin–resistance syndrome (Syndrome X). Diabetes 1992; 41: 715–22.
148. Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
149. Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 1999; 83: 17F–21F.
150. Haffner SM, Stern MP, Hazuda HP et al. Increased insulin concentration in nondiabetic offspring of diabetic parents. New Engl J Med 1988; 319: 1297–301.
151. Haffner SM, Ferranini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992; 20: 38–45.
152. Han TS, van Leer EM, Seidell JC et al. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401–5.
153. Haneda M, Polonsky KS, Bergenstal RM et al. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med 1984; 310: 1288–94.
154. Haneda T, Ido A, Fijikane T, et al. Effect of bisoprolol, a b1-selective b-blocer, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jpn J Geriat 1998; 35: 33–8.
155. Hansen D, Toubro S, Stock M et al. The effect of sibu–tramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23 (10): 1016–24.
156. Hansson L. The Hypertension Optimal Treatment study (the HOT Study). Blood Press 1999; 2: 62–8.
157. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
158. Hansson L et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. The Lancet 1998; 351: 1755–62.
159. Hansson L, Lindholm L, Niskanen L et al. Effects of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertensyin: CAPPP randomized trial. Lancet 1999; 353: 611–6.
160. Haw TS, van Leer EM, Seidell JC, Lean ME.J Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401–5.
161. Heinemann L, Heise T, Ampudia J et al. Four week administration of an ACE inhibitor and a cardioselective b-blocker in healthy volunteers: no influense on insulin sensitivity. Eur J Clin Invest 1995; 25: 595–600.
162. Heinonen TM, Stein E, Weiss SR et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study. Clin Ther 1996; 18: 853–63.
163. Henefeld M, LeonhardtW. Das metabolische Syndrome. Deutsch Ges Wes 1980; 36: 545–51.
164. Higgins M, Kannel W, Garrison R et al. Hazards of obesity: the Framingham experience. Acta Med Scand 1987; 723: 235–365.
165. Hilleman DE, Seyedroubari A. Atorvastatin: a potent new HMG-CoA reductase inhibitor. CVR&R 1998 (May); 32–48.
166. Himsworth H. Diabetes mellitus; a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 1(I): 127–30.
167. Himsworth HP. Diabetes mellitus. Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 1: 127–30.
168. Ho CH, Jap TS. Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comperisom with healthy controls. Thromb Haemost 1991; 65: 3–6.
169. Holl A, Mangels W, Dreyer M. Biguanide treatment increase the number of insulin receptor sites on human erythrocytes. N Engl J Med 1981; 305: 563–6.
170. Hollander P, Elbein S, Hirsch I et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288–94.
171. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001 Nov–Dec; 17(6): 467–73.
172. Hone J, Accili D, Al-Gazali LI et al. Homozygosity for a new mutation (ILe – Met) in the insulin receptor gene in five sibs with familial insulin resistance. J Med Genet 1994; 31: 715–6.
173. HOPE Study Investigators. Effects of ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
174. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–15.
175. Houston MC. The Effects of antihypertensive drags on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988; 115; 3: 640–56.
176. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613–28.
177. Hubert HB, Feinleib M, McNamara PM et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983; 67: 968–77.
178. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s diseas of the omentum”? Lancet 1997; 349 (9060): 1210–3.
179. Jackson TK, Garrison JC. The Pharmacological Basis of Therapeut. Eds J Hardman et al 9-th ed. New York 1996; 733–58.
180. Janssens WJ, Geyskens D, Proost F. Comparison of the b-adrenergic antagonistic effects of Nebivolol, carvedilol, celiprolol and bisoprolol on isolated right atria and trachea of the guinea-pig. Preclinical Research Report. June 1996.
181. Jenings PE, Scott NA, Saniabadi AR, Belch JJF. Effects of gliclazide on platelet reactivity and free radicals in type 2 diabetic patients: clinical assessment. Metabolism 1992; 41 (5 Suppl. 1): 36–39.
182. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemic agents. Diabetes Care 1989; 12: 201–208.
183. Jennings G et al. Effects of Nebivolol on haemodynamics, cardiac dimensions and function, cardiovascular reflexes and biochemical measures of sympathetic activity in normal human subjects. Drug Invest 1991; 3 (Suppl. 1): 51–9.
184. Johnson BF. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol 1982; 4 (Suppl. 2): S213–21.
185. Jonas M, Reicher-Reiss H, Royko V et al. Usefullness of b-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77:1273–7.
186. Jones P, Kafonek S, Laurora I et al. Comparitive dose efficacy study of atorvastatin with that of lovastatin, pravastatin, simvastatin, and fluvastatin in patients with hypercholesterolemia: The CURVES stud. Am J Cardiol 1998; 81: 582–7.
187. Julius S, Gudbrandsson T, Jamerson K, Shahab ST, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991, 9: 983–6.
188. Kamide K, Hori M, Zhu J et al. Insulin-mediated growth in aortic smooth muscle and the vascular rennin-angiotensin system. Hypertension 1998; 32: 482–7.
189. Kannel WB, Cuppels LA, Ramaswami R et al. Regional obesity and risk of cardiovascular disease; the Framingham study. J Clin Epidemiol 1991; 44(2): 183–90.
190. Kannel WB, McGee DL. Diabetes and glucose intolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979; 2: 120–6.
191. Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20.
192. Karbonits M. Leptin levels do not change acutely with food administration, but area negatively correlated with pituitary activity. J Endocrinol 1997, 152: 39.
193. Kelley D, Bray G, Xavier F et al. Clinical efficacy of orlistat therapy in overweigh and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002; 25: 1033–41.
194. Kelley DE, Bidot P, Freedman Z et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes care 1998; 21: 2056–61.
195. Keltikangas-Jarvinen L. Vital exhauston, anger expression, pituatry and adrenocortical hormones. Implications for the insulin resistance syndrime: Atherosclerosis, Thrombosis and Vascular Biology 1996; 16: 273–88.
196. Kern PA, Saghizadeh M, Ong JM et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111–19.
197. Kopf D, Muhlen I, Kroning G et al. Insulin sensitivity and sodium excretion in normotensive offspring and hypertensive patients. Metabolism 2001; 50(8): 929–35.
198. Krotkiewski M, Bjomtorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. J Clin Invest 1983; 72: 1150–62.
199. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. JAMA 1994; 272: 205–11.
200. Laakso M. Epidemiology of Diabetic Dyslipidemia. Diabetes Rev 1995; 3: 408–22.
201. Laakso M, Edelman SV, Brechtel G, Baron A.D. Decreased effect of insulin to stimulate skeletal blood flow in obese man: a novel mechanism for insulin resistance. BMJ 1990; 85: 1844–52.
202. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992; 41: 1076–83.
203. Lapidus L, Bengtsson C, Larsson B et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 1984; 289: 1257–61.
204. Lapidus L, Bengtsson C, Larsson B et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow–up participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1261–3.
205. Laragb JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use off rennin and aldosterone profiles. Am J Med 1973; 55: 261–74.
206. Larsson B, Svardsudd K, Welin L et al. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: a 13 year follow-up participants in the study of men born in 1913. BMJ 1984; 288: 1401–4.
207. Larsson B, SvКrdsudd K, Welin L et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born 1913. Br Med J 1984; 1: 1401–4.
208. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53: 828–47.
209. Lehto S, Ronnemaa T et al. Dislipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354–9.
210. Lembo G, Rendina V. Acute noradrenergic activation induces insulin resistence in human skeletal muscle. Am J Physiol 1994; 266: E242–7.
211. Lender D, Arauz-Pacheco C, Breen L et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298–303.
212. Lerch M, Weidmann P, Ho MP, Gerber P. Metabolic effect of temocapril in hypertensive patients with diabetes mellitus type 2. J Cardiovasc Pharmacol 1999; 33: 527–33.
213. Lievre M, Gueret P, Gayet C et al. Ramipril-inducet regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92–7.
214. Lievre M, Gueret P, Gayet C. Hypertrophie cardiaque et ramipril. Hypertension 1995; 25: 92–7.
215. Lillioja S, Motl DM, Zawadzki JK et al. In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes 1987; 36: 1329–35.
216. Lindsted K, Towstad S, Kuzma JW. Body mass index and patterns of mortality among Seventh-Day Adventist men. Int J Obesity 1991; 15: 397–406.
217. Lissner I, Bengtsson C, Lapidus L, Kristjansson K, Wedel H. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20: 797–801.
218. Loaldi A, Polese A, Montorsi P et al. Comperison of nifidipine, propranolol and isosorbid dinitrate on angiographic progression and regression of coronary nerrowings in angina pectoris. Am J Cardiol 1989; 64: 434–9.
219. Lotti G, Gianrossi R. Moxonidine vs Captopril bei leichter bis mittelschwerer hypertonie. Fortscher Med 1993; 111: 429–32.
220. Louis WJ et al. A study to establish the acute effects of Nebivolol on blood pressure and whether or not there are first dose postural effects in middle aged and elderly patients. Unpublished report on NEB–AUS–3, March 1995.
221. Mabry CC, Hollihgworth DR. Failure of hypophysectomy in generalized lipodyctrophy. J Pediatr 1972; 81.
222. Mack TM, Handerson BE, Gerkins VR. Reserpine and breast cancer in a retirement community. N Engl J Med 1975; 292: 1366–71.
223. Malaguarnera Y, Giugno I, Ruello P et al. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias. Br J Clin Pharmac 1999; 48: 605–9.
224. Mallion JM, Asmer R, Boutelant S et al. Twenty-four hour antihypertensive efficacy of indapamide 1,5 mg sustained release: results of two randomized double-blind controlled studies. J Card Pharmacol 1998; 32: 373–432.
225. Mallion JM, Gaudemaris RD et al. Day and night blood pressure values in normotensive and essential hypertensive subjects assessed by twenty-four-hour ambulatory monitoring. J Hypertens 1990; 8: 49–55.
226. Mamo J, Szeto L, Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990; 33: 339.
227. Mari A. Assessment of insulin sensitivity with minimal model: role of model assumption. Am J Physiol 1997; 272: E925–34.
228. Mark A, Correia M, Morgan D et al. Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999; 33: 537–41.
229. Marre M, Fernandez M, Garcia-Puig J et al. Value of natrilix SR in hypertensive type 2 diabetic patients with microalbuminuria. J Hypertens 2002; 20 (Suppl. 4): S338.
230. Materson B.J., Reda D.J., Cushman W.C., et al. Single – drug – therapy for hypertension in men: a comparison of six antyhypertensive agents with placebo. VA Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 1171–4.
231. Matsukawa T, Mano T, Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Invest 1993; 92: 25–8.
232. Matthaei S, Hamann A, Klein H et al. Association of metformin`s effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 1991; 40 (7): 850–7.
233. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
234. Mattiasson I, Berntrop K, Lindgarde F. Sodium-lithium countertransport and platelet cytosolic free calcium concentration in relation to peripheral insulin sensitivity in postmenopausal women. Clin Sci 1992; 83: 319–24.
235. Mayer I. Overweight: causes, costs and control. Englewood clifts. 1998. New Jersy: Prentice–Hall; 213 p.
236. McCann U, Seiden L, Rubin L, Ricaurte G. Brain Serotonin Neurotoxicity and Primary Pulmonary Hypertension From Fenfluramine and Dexfenfluramine. JAMA 1997; 278: 666–72.
237. McKay S et al. Acarbose decreases glucose entry rate and increase glucose oxidation, a U13C-glucose study. Diabetes 1999; 48 (suppl. 5): A 110.
238. Mehnert H, Kuhlmann H. Hypertonie and Diabetes mellitus. Deutsch Med J 1968; 19: 567–71.
239. Meigs J, Mittleman M et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221–8.
240. Meneilly et al. Effects of acarbose on insulin sensitivity in elderly patients with diabetes. Diab care 2000; 23: 1162–67.
241. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes, data from a 5-year surveillance study. Diab Res Clin Pract 2001: 193–204.
242. Moller D, Bjorback S, Vidal-Puig A. Candidate genes for insulin resistance. Diabetes Care 1996; 19: 396–400.
243. Moller D, Flier J. Insulin resistance – mechanisms, syndromes, and implications. N Engl J Med 1991; 325 (13): 938–48.
244. Molner D. Insulin secretion and carbohydrate tolerance in childhood obesity. Consilium medicum 1990; 202.
245. Montaguti U, Celin D, Ceredi C. Efficacy of the long-term administration of metformin in hyperlipidaemic patients. Res Clin Forums 1979; 1(1): 95–103.
246. Muller G. The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl. Molecular Medicine 2000; 6(11): 907–33.
247. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997; 272: 10,585–93.
248. Muller-Wieland D, Taub R et al. Insulin-receptor gene and its expression in patients with insulin resistance. Diabetes 1989; 38: 31–8.
249. Muscelli E, Emdin M, Natali A et al. Cardiac responses to insulin in vivo: influence of obesity. J Clin Endocrinol Metab 1998; 83: 2084–90.
250. Mychka V, Gornostaev V, Bogieva R, Chazova I. Glimepiride in patients with Type 2 diabetes mellitus and numerous cardiovasculary risk factors. 18-th International Diabetes Federation Congress, Paris, France from 24 – 29 August 2003.
251. Mychka V, Gornostaev V, Bogieva R, Chazova I. Glimepiride in patients with arterial hypertension, obesity and type 2 diabetes mellitus. 13-th European meeting on Hypertension, Milan, Italy, June 13–17 2003.
252. Mychka V, Gornostaev V, Mikheev V, Sergienko V, Chazova I. Study of brain perfusion in patients with arterial hypertension and metabolic syndrome using single photon emission computed tomography method. XII European meeting on hypertension, Milan, Italy June 15–19, 2001, p. 65.
253. Mychka V, Gornostaev V, V. Dmitriev, Sheinina N, Chazova I. Effect of perindopril on 24-hours ambulatory blood pressure monitoring, carbohydrates and lipids metabolism in patients with mild and moderate arterial hypertension and metabolic syndrome. XII European meeting on hypertension, Milan, Italy June 15–19 2001; 282.
254. Myers MG. A dose-response snudy of perindopril in hypertension: effect on blood pressure 6 and 24 hours after dosing Can J Cardiol 1996; 12: 1191–6.
255. Natali A, Quinones Galvan A, Azzili F et al. Renovascular hypertension and insulin sensitivity. Eur J Clin Invest 1996; 26: 556–63.
256. National Task Force on the Prevention and Treatment of Obesity. Long term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907–15.
257. Neal B, MacMahon S. PROGRESS (Perindopril pROtection aGainst Recurrent Stroke Study): rationale and design J Hypertens 1995; 13: 1869–73.
258. Neaton JD, Grimm RHJr, Prineas RJ et al. Treatment of Mild Hypertension study. Final results. JAMA 1993; 270: 713–24.
259. Neel JM. Diabetes mellitus: a thirty genotype redered detrimental by “progress”? Am J Hum Genet 1962; 14(2): 353–62.
260. Neel JM. Diabetes mellitus: a thrifty genotype rendered detrimental by “progress”? Am J Hum Genet 1962; 14(2): 353–62.
261. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscl Thromb 1993; 13: 1822–8.
262. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91 (3): 764–70.
263. Nosadini R, Avogaro A, Trevisan R. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type 2 diabetes. Diabetes Care 1989; 10: 62.
264. Ogawa Y. CNS Mediators of leptin action. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
265. Olsson A. Addressing the challenge. Eur Heart J 1998; 19: 29–35.
266. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, Haring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 2002 Nov; 25 (11): 2065–73.
267. Packer MO, Connor C, Ghali J et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure New Engl J Med 1996; 335: 1107–14.
268. Palmer KJ, Brogden RN. Gliclazide, in update on its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46: 92–125.
269. Papageorgiou A, Karayannis A, Athyros V et al. A comparatuve study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension. Drug invest 1994; 7 (1): 396–404.
270. Periello G. Mechanisms of metformin action in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1995; 11(Suppl. 1): S51–6.
271. Petersen JS, DiBona GF. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension 1996; 27 (3Pt2): 619–25.
272. Piatti PM, Monti LD et al. Forearm insulin-and-non-insulin mediated glucose uptake and muscle metabolism in man: role of free fatty acids and blood glucose levels. Metab Clin Exp 1991; 40: 926–33.
273. Pickup JC, Crook MA ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999; 42: 903–19.
274. Pickup JC, Crook MA. Is Type II diabetes mellitus a disease of innate immune system? Diabetologia. 1998; 41: 1241–48.
275. Pi-Sunjyer FX. Medical hazards of obesity. Ann Intern Med. 1993; 119 (7pt2): 655–660.
276. Plosker GL , Sorcin EM. Quinapril: a review of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994 Aug ; 48(2) : 227–52.
277. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39(2): 167–74.
278. Prichard BNC. Clinical pharmacology of moxonidine. In van Zwieten PA. edit. The I1-imidazolin receptor agonist moxonidine. 2nd Edition. London: Roy Soc Med 1996; 31–47.
279. Prichard BNS, Simmons R, Rooks MJ et al. A double – blind comparison of moxonidine and atenolol in the management of patients with mild – to – moderate hypertension. J Cardiovsc Pharmacol 1992; 20 (Suppl. 4): S45–9.
280. Prochazka M, Lillioga S, Tait J et al. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993; 42: 514–19.
281. Pueyo C, Diaz C, Sol JM et al. The efficacy and safety of quinapril in the treatment of moderate to severe and severe hypertension: comparison to captopril. Clin Cardiol 1990 Jun 13(6) (Suppl. 7): 26–31.
282. Purnell J, Brunzell J The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Curr Opin Lipidol. 1997; 8(1): 17–22.
283. Pyorala K, Pedersen T et al. Chlesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20.
284. Rackley CE. Monotherapy with HMG–CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19: 683–9.
285. Randle PJ, Garland P, Hales C et al. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; 1: 785–89.
286. Randle .J, Priestman DA, Mistry SC et al. Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem 1994; 55: 1–11.
287. Reaven G. Diet and Syndrome X. Curr Atheroscler Rep 2000; 2 (6): 503–7.
288. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
289. Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormali-
ties – the role of insulin resistance and the sympatoadrenal system. N Engl J Med 1996; 334: 374–81.
290. Resnick L. The cellular ionic basis of hypertension and allied clinical conditions. Prog Cardiovasc Dis 1999; 42(1): 1–22.
291. Richard PD, Trevor JO. Hyperinsulinemia and resistance : associations with cardiovasculars and disease. Cardiovasc risc factors 1993; 1: 12–18.
292. Robertson RP, Olson LK, Zhang HJ et al. Differentiating glucose toxity from glucose desensitization; a new message from insulin gene. Diabetes 1994; 43 (9): 1085–9.
293. Rosak C et al. The effect of the timing and and the administration of acarbose on postprandial hyperglycaemia. Diab Med 1995; 12: 979–84.
294. Rowe JR, Young JB, Minaker KL et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219–25.
295. Rubin HB, Robin SJ et al. For the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrosil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–18.
296. Ruggcnenti P, Pcarna A, Gherardi G et al. Properties of ACE–inhibition in non-diabetic nephropathies with non-nephronic proteinuria. Lancet 1999; 354: 359–64.
297. Saghizadeh M, Ong JM, Garvey WT et al. The expression TNF-a by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97: 1111–16.
298. Sakamoto T, Woodcock-Mitchell J, Marutsuka K, Mitchell JJ, Sobel BE, Fujii S. TNF-a and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Physiol 1999; 276 (6Pt1): C1391–7.
299. Scheen AJ, Letiexhe MR. Effects of metformin in obese patients with impared glucose tolerance. Diabet Metab Rev 1995; 11: S69–80.
300. Scherrer U, Sarfori C. Insulin as a vascular and sympathoexifatory hormone: implications for blood pressure regulation, insulinsensitivity and cardiovascular morbidity. Circulation, 1997; 96;11: 4104–13.
301. Scholtz GH, Schneider K, Knirsch W et al. Efficacy and Tolerability of Glimepiride in Daily Practice: A Non-Interventional Observational Cohort Study. Clin Drug Invest 2001; 21(9): 597–604.
302. Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension N Engl J Med 2000; 343: 1969.
303. Schwartz MW, Kahn SE. Insulin resistance and obesity. Nature 1999; 402: 860–1.
304. Schwartz MW, Figlewicz DP, Baskin DB et al. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 1992; 13: 81–113–741.
305. Seidell JS, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997; 53: 238–252.
306. Selby JV, Austin MA et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993; 88: 381–7.
307. Seltzer M, Allen W, Herron A et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967; 46: 323–30.
308. Sharma AM, Ruland K, Spies KP et al. Salt sensitivity in young normotensive subjects is associated with a hyperinsulinemic response to oral glucose. J Hypertension 1991; 9: 329–35.
309. Shaw JE, Zimmet PZ, de Courten M et al. Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care 1999; 22: 399–402.
310. Sheinina N, Yaskova K, Mychka V, Chazova I. Experience with application of an angiotensin converting enzyme inhibitor perindopril in patients with mild to moderate arterial hypertension and metabolic syndrome. 19-th Scientific Meeting of the International Society of Hypertension; 12 th European Meeting on Hypertension; June 23–27, 2002. Prague
311. Silverstone T. Appetite suppressants. Drugs 1992; 43(6): 820–36.
312. Sims EA, Danforth E, Norton ES et al. Endocrine and metabolic effects of experimental obesity in man. Rec Prog Harm Res 1973; 29: 457–96.
313. Sjostroem C, Lissner L, Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Оbes Res 1997; 5: 519–30.
314. Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–72.
315. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991; 9: 217–23.
316. Snorgaard O, Kober L, Carlsen J The effects of matformin on blood pressure and metabolism in non-diabetic hypertensive patients. J Intern Med 1997; 242 (5): 407–12.
317. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040–4.
318. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B–9.
319. Steinbrecher UP, Witztum JL et al. Comparison of glucosylated LDL with methylated or cyclohexanedione-treated LDL in the measurement of receptor independent LDL catabolism. J Clin Invest 1983; 71: 950–5.
320. Steiner G. Altering triglyceride concentration changes insulin-glucose relationships in hypertriglyceridemic patients. Double–blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14: 1077–81.
321. Steiner G. Diabetes and atherosclerosis: an overview. Diabetes 1981.
322. Steiner G. The dys lipoproteinemias of diabetes. Atherosclerosis 1994; 110 (Suppl): S 27–33.
323. Stephens TW, Basinski M, Bristow PK et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530–2.
324. Stern M. Epidemiology of obesity and its link to heart disease. Metabolism 1995; 44(Suppl. 3): 1–3.
325. Stevens J, Cai J, Pamuk E et al. The effect of age on the association between body–mass index and mortality. N Engl J Med 1998; 338: 1–7.
326. Stout RW, Beierman EI, Ross R. The effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975; 36: 319–27.
327. Stumpe K, Overlack A. Perindopril therapeutic safety study. Am J Cardiol 1993; 71: 32E–7E.
328. Summary of the Second Report of the Nanional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalution, and Treatment of High Blood Cholesterol in Adults. Exrert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993; 269: 3015–23.
329. Sundaresan P, Lykos D, Daher A at al. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care 1997 May; 20(5): 692–7.
330. Syvanne V, Taskinen M. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 (Suppl. 1): 20–23.
331. Taddei S, Virdis A, Chiadoni L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21: 22–9.
332. Takada Y, Urano T,Watanabe I. Taminato A., Yoshimi T, Takada A. Changes in fibrinolitic parameters in male patients with type 2 diabetes mellitus. Thromb Res 1993; 71: 405–15.
333. Taskinen M. R. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992; 41(Suppl. 2): 12–7.
334. Taskinen MR, Lahdenperi S, Syvanne M. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28; 335–40.
335. Tatti P et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579–603.
336. Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FASET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
337. Taylor SL. Lilly lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41: 1473–490.
338. Theodor R, Weimann HJ, Weber W et al. Absolute bio-availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16: 153–9.
339. Thijs L, Staessen J, O’Brien E et al. The ambulatory blood pressure in normotensive and hypertensive subjects: results from an international database. Netherl J Med 1995; 46 (2): 106–14.
340. Tikkanen MJ, Laakso M et al. Treatment of hypercholesterolemia and combined hyperlipidemia with Simvastatin and Gemfibrozil in patients with NIDDM. Diabetes Care 1998; 21: 477–481.
341. Trenk D, Wagner F, Jahnchen E et al. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin. Pharmacol 1987; 27: 988–93.
342. Trenkwalder P, Elmfelolt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs – felodipine and metaprolol. J Hum. Hypertension 1995; 9 (Suppl. 2): 37–42.
343. Trials of Hypertension Prevention Collaborativi Research Group. Effect of weight loss and sodium reduction intervention in blood pressure and hypertension incidence in overweight people with high–normal blood pressure: the Trials of Hypertension Prevention phase II. Arch Intern Med 1997; 157: 657–67.
344. Trisshita V, Gullo D, Pezzino V et al. Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type 2 diabetic patients. J Clin Endocrinol Metab 1983; 57: 713–8.
345. Tritos NA, Mantzoras CS. Leptin: its role in obesity and beyond. Diabetologia 1997; 40: 1371–79.
346. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
347. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713–9.
348. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obecity – induced insulin resistance in mice. Lacking TNF-a function. Nature 1997; 389: 610–4.
349. Vague J. Amer Clin Nutr.1996; 4: 20–8.
350. Vague J. The degree of masculine differentiation of obesities, a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4: 20–34.
351. Vague P, Juhan-Vague I, Alessi MC et al. Metformin decreases the high plasminogen activator inhition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 1987; 57(3): 326–8.
352. Van De Water A et al. Pharmacological and hemodynamic profile of Nebivolol, a chemically novel, potent, and selective b1-adrenergic antagonist. J Cardiovasc Pharm. 1988; 11: 552– 63.
353. Van Nueten J.M et al. In vitro pharmacological profile of R065824, a potent and selective b1-adrenergic antagonist. JRF Preclinical Research Report R065834/8. November 1985.
354. Van Nueten L et al. Nebivolol versus nifedipine in treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Therapeutics. 1998; 5: 237–43.
355. Van Rooy P et al. Phase I study: effects of Nebivolol 10 mg and 20 mg versus placebo on heart rate, blood pressure, systolic time intervals and side effects. A double-blind placebo-controlled cross-over study in healthy volunteers. JRF Clinical Research Report on R67555 NO–32. January 1989.
356. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA 1970; 213 (7): 1143–52.
357. Vulpis V, Antonacci A, Prandi P et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non–insulin dependent diabetes mellitus. Minerva Med 1991; 82: 189–93.
358. Wadworth AN, Brogden RN. Quanapril: a review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 1991; 41 (3): 378–99.
359. Warram JH, Martin BC, Krolewski AS et al. Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents. Ann Int Med 1990; 113: 909–15.
360. Wassertheil-Smoller S, Oberman A, Blaufox MD et al. The trial of antihypertensive ineterventions and management (TAIM) study. Final results to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992; 5: 37–44.
361. Weber MA. Interrupting the RAS:the role of iACE and angiotensin II receptor antagonists in the treatment of hypertension Am J Hypertens 1999 Dec; 12 (12pt3): 189S–94S.
362. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drug safety, 2001; 24: 1155–65.
363. Weidmann P, de Courten M, Bohlen L. Insulin resistance, hyperinsulinaemia and hypertension. J Hypertens1993; 11(Suppl. 5): S27–38.
364. Weigle DS et al. Secretory products of adypocites modulate multiple physiological functions. Ann Endocrinol, Paris 1997; 58: 132–6.
365. Weissman N, Tighe J, Gottdiener J, Gwynne J et al. Prevalence of valvular-regurgitation associated with dexfenfluramine three to fine months after discontinuation of treatment. J Am Coll Cardiol 1999 Dec; 34(7): 2088–95.
366. Welch S, Gebhart SSP, Bergman RN et al. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocr Metab 1990; 71: 1508–18.
367. Widen E, Ekstrand A et al. Insulin – resistance in type 2 diabetic patients with hupertriglycerdemia. Diabetologia 1992; 35: 1140–34.
368. Widen E, Lehto M, Kannen T et al. Association of a polymorphism in the b3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. New Engl J Med 1995; 333: 348–51.
369. Willett W.C., Manson J.E., Stampfer M.J et al. Weight, weight change, and coronary heart disease in women. Risk within the normal weight range. J Am Med Assoc 1995; 273: 461–5.
370. Williams RR, Feinleib M, Connor RJ, et al. Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Natl Cancer Inst 1978; 61: 327–35.
371. Willms B, Ruge D. Comparison of acarbose and metformin in patient with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diab Med 1999; 16 :755–61
372. Wimann H-J, Rudolph M. Clinical phrmacokinetics of moxonidine. J Cardiovacs Pharmacol 1992; 20: S37–S41.
373. World Health Organisation. Obesity: Preventing and managing the global epidemic. WHO (Geneva) 1998.
374. World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and ins Complications. Geneva, World Health Organization, 1999.
375. Yamada Y, Miyajima E, Tochikubo O et al. Age related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989; 13: 870–77.
376. Yamazaki T, Komuro I, Zou Y et al Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine. Hypertension 1998; 31: 32–8.
377. Yaskova K, Sheinina N, Mychka V, Chazova I. Effect of orlistat (Xenical) on blood pressure in patients with mild and moderate arterial hypertension and metabolic syndrome. 19th Scientific Meeting of the International Society of Hypertension; 12 th European Meeting on Hypertension; June 23–27, 2002, Prague.
378. Zanchetti A. Trough: peak ratio of the blood pressure response to dihydropiridine calcium antagonists. J Hypertens 1994; 12(8): S97–106.
379. Zannad F, Bernaud CM, Fau R. Double-blind randomized multicentre comparibeyond in patients with mild to moderate hypertension. J Hypertens 1999; 17: 137–46.
380. Zannad F, Matzinger A, Laeche J. Throug/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists Am J Hypertens 1996; 9: 633–64.
381. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013–917.
382. Zhi J, Melia A, Guerciolini R et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82–5.
383. Горностаев В.В., Мычка В.Б., Михеев В.Э., Сергиенко В.Б., Чазова И.Е. Исследование перфузии головного мозга у больных артериальной гипертонией и метаболическим синдромом методом однофотонной эмиссионной компьютерной томографии. VIII Всероссийский съезд неврологов. Казань, 22 – 24 мая 2001.
384. Дмитриев В., Гуртуева М., Арабидзе Г., Рогоза А, Мычка В. Лечение эссенциальной гипертонии (мягкой и умеренной формы течения) ОСМО-Адалатом. Всероссийская научно-практическая конференция “Актуальные проблемы артериальной гипертонии (памяти Г.Г. Арабидзе)” Москва 7–8 декабря 1999; 51.
385. Кабак Я.М., Гозе Г. Островковый аппарат поджелудочной железы у крыс при “гипоталамическом ожирении”. Бюл экспер биологии и медицины 1962; 8.
386. Мычка В.Б. Артериальная гипертония и ожирение. Consilium provisorum 2002; 5.
387. Мычка В.Б. Артериальная гипертония и ожирение. Сonsilium provisorum 2002;5:18–21.
388. Мычка В.Б., Богиева Р.М., Мамырбаева К.М., Чазова И.Е. Терапия акарбозой как профилактика множественных сердечно-сосудистых факторов риска метаболического синдрома. Артериальная гипертензия 2003; 9(2).
389. Мычка В.Б., Богиева Р.М., Чазова И.Е. Акарбоза – средство профилактики множественных сердечно-сосудистых факторов риска метаболического синдрома. Клин. фармакол. и тер. 2003; 12(2) 80–3.
390. Мычка В.Б., Горностаев В.В., Чазова И.Е. Сердечно-сосудистые осложнения сахарного диабета 2 типа. Кардиология 2002.
3
91. Мычка В.Б., Горностаев В.В., Шикина Н.Ю., Чазова И.Е. Артериальная гипертония и ожирение. Consilium medicum, (Прил. 2), 2001.
392. Мычка В.Б., Горностаев В.В.,Чазова И.Е. Влияние монотерапии логимаксом на показатели суточного мониторирования артериального давления, углеводного и липидного обмена у больных мягкой и умеренной артериальной гипертонией и сахарным диабетом 2 типа. Российский национальный конгресс кардиологов, 8–11 октября 2002.
393. Мычка В.Б., Горностаев, В.В., Богиева Р.М., Чазова И.Е.. Артериальная гипертония у больных сахарным диабетом 2 типа и метаболическим синдромом. Consilium Medicum. Приложение Артериальная гипертония 2001; 1:25–30.
394. Мычка В.Б., Дмитриев В.В., Шейнина Н.В., Горностаев В.В., Чазова И.Е. Влияние монотерапии периндоприлом на уровень артериального давления и показатели липидного обмена у больных метаболическим синдромом. Материалы Всероссийской научно-практической конференции “Современные возможности эффективной профилактики, диагностики и лечения артериальной гипертонии” 2001, с. 103.
395. Мычка В.Б., Масенко В.Б., Творогова М.Г., Шейнина Н.В., Чазова И.Е. Применение периндоприла у больных мягкой и умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия 2002; 8(1) .
396. Мычка В.Б., Творогова М.Г., Чазова И.Е. Применение глимепирида (амарила) у больных сахарным диабетом типа 2 со множественными факторами сердечно-сосудистого риска. Клин. фарм. и тер. 2003; 12 (2): 83–7.
397. Мычка В.Б., Творогова М.Г., Чазова И.Е. Эффективность амарила у больных сахарным диабетом типа 2, ожирением и артериальной гипертонией. Артериальная гипертензия 2003.
398. Мычка В.Б., Творогова М.Г., Яськова К.Н., Чазова И.Е. Терапия ксеникалом больных артериальной гипертонией и метаболическим синдромом. Артериальная гипертензия 2002; 8(1).
399. Мычка В.Б., Чазова И.Е. b-Блокаторы и сахарный диабет. Артериальная гипертензия 2002; 8(5).
400. Мычка В.Б., Чазова И.Е. Правильное питание – путь к здоровью. Рекомендации для пациентов. М., 2002.
401. Мычка В.Б., Яськова К.Н., Чазова И.Е. Эффект орлистата на уровень артериального давления и показатели углеводного и липидного обменов у больных артериальной гипертонией и метаболическим синдромом. Российский национальный конгресс кардиологов, М., 9–11 октября 2001.
402. Нечаев А.С., Доборджгинидзе Л.М., Рижинашвили А.М., Грацианский Н.А. Опыт применения нового ингибитора ГМГ–КоА-редуктазы аторвастатина. Клин. фарма. и тер. 1999; 4: 27–31.
403. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артериальная гипертензия 2001; 7:1(приложение): 1–16.
404. Соколова Л.А., Русанов О.А., Винник Т.А. и др. Влияние моксонидина на показатели геодинамики и уровень инсулина крови у больных мягкой и умеренной артериальной гипертензией (результаты 6-месячной терапии). Артериальная гипертензия 2000; 6(1): 59–62.
405. Старкова Н.Т., Долгов В.В., Давыдов А.Л. и др. Влияние гиполипидемической терапии на состояние углеводного и липидного обмена и их гормональных регуляторов у больных сахарным диабетом 2 типа. Проблемы эндокринологии 2003; 1: 24–6.
406. Чазова И.Е. Комбинированная терапия артериальной гипертензии. Consilium Medicum. Приложение “Артериальная гипертензия 2001; 2: 22–6.
407. Чазова И.Е. Российская многоцентровая программа ПРИЗ – изучение антигипертензивной эффективности и переносимости периндоприла в широкой клинической практике. Consilium medicum 2002 (4): 3: 125–9.
408. Чазова И.Е., Мычка В.Б, Творогова М.Г., Шейнина Н.В. Престариум: клинические преимущества при лечении больных с артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия и диабет 2003; 2.
409. Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Артериальная гипертензия 2002; 8(1).
410. Чазова И.Е., Мычка В.Б. Метаболический синдром. Consilium medicum 2002; 4(11)587–92.
411. Чазова И.Е., Мычка В.Б. Метаболический синдром. Кардиоваскулярная терапия и профилактика 2003; 3: 32–8.
412. Чазова И.Е., Мычка В.Б., Горностаев В.В. Применение комбинированного препарата логимакс у больных с мягкой и умеренной артериальной гипертензией и сахарным диабетом 2 типа. Артериальная гипертензия 2002; 8(3).
413. Чазова И.Е., Мычка В.Б., Стукалова О.В., Синицин В.Е. Роль ингибиторов АПФ в лечении сахарного диабета типа 2: фокус на аккупро. Артериальная гипертония 2003; 8(6): 209–11.
414. Чазова И.Е., Мычка В.Б., Творогова М.Г., Шейнина Н.В. Престариум: клинические преимущества при лечении больных артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия и диабет 2003; 2: 9–10.
415. Чазова, И.Е., Мычка В.Б., Горностаев В.В., Двоскина И.М., Сергиенко В.Б. Цереброваскулярные осложнения у больных артериальной гипертензией: первичная и вторичная профилактика. Consilium medicum 2003; 5(2): 61–4.
416. Шейнина Н.В., Мычка В.Б., Дмитриев В.В., Горностаев В.В., Чазова И.Е. Применение периндоприла у больных с мягкой и умеренной формами артериальной гипертонией и метаболическим синдромом. Материалы Всероссийской научно-практической конференции Современные возможности эффективной профилактики, диагностики и лечения артериальной гипертонии 2001; с. 103.
417. Шейнина Н.В., Мычка В.Б., Чазова И.Е. Эффект периндоприла на инсулиновый спектр крови у больных мягкой и умеренной артериальной гипертонией и метаболическим синдромом. Международная конференция молодых врачей, Армения, Ереван, 17–22 сентября 2001; 11.
418. Яськова К.Н., Мычка В.Б., Масенко В.П., Чазова И.Е., Творогова М.Г. Использование инсулин-модифицированного внутривенного глюкозо-толерантного теста для диагностики инсулинорезистентности у пациентов с метаболическим синдромом. Клиническая лабораторная диагностика, 2003; 11.
419. Яськова К.Н., Мычка В.Б., Чазова И.Е. Влияние периндоприла на липидный обмен у пациентов с мягкой и умеренной артериальной гипертонией и метаболическим синдромом. Международная конференция молодых врачей, Армения, Ереван, 17–22 сентября 2001; 13.
420. Яськова К.Н., Мычка В.Б., Чазова И.Е., Творогова М.Г. Внутривенный глюкозо-толерантный тест в диагностике инсулинорезистентности у пациентов с метаболическим синдромом. Клиническая лабораторная диагностика 2003; 10.
421. Яськова К.Н., Мычка В.Б., Чазова И.Е., Творогова М.Г. Инсулинорезистентность и методы ее диагностики. Лабораторная медицина 2003; 6.



В начало
/media/book/04_01/145.shtml :: Sunday, 14-Nov-2004 23:13:04 MSK
© Издательство Media Medica, 2000. Почта :: редакция, webmaster